A carregar...
Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial
This single-arm, phase II trial is to investigate efficacy and safety of nab-paclitaxel plus S-1 as first-line treatment in advanced pancreatic cancer. Nab-paclitaxel was administered at 120 mg/m(2) intravenously on day 1 and 8, S-1 was given twice a day orally on day 1-14 of each 21-day cycle, for...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5696191/ https://ncbi.nlm.nih.gov/pubmed/29190925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21359 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|